(ATRC) AtriCure - Ratings and Ratios

AtriCure, Inc. (NASDAQ:ATRC) is a medical device company specializing in innovative solutions for cardiac surgery and electrophysiology. Their primary focus is on developing tools for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporary pain relief through peripheral nerve ablation. The company serves medical centers globally, with a strong presence in the United States, Europe, and the Asia-Pacific region.

Their product portfolio is extensive and targeted. Key offerings include the Isolator Synergy Clamps for cardiac tissue ablation, single-use disposable radio frequency products, and the MAX Pen device. The MAX Pen is particularly notable as a multifunctional tool that allows surgeons to evaluate arrhythmias, perform pacing and sensing, and ablate tissue—all with a single device. Additionally, the Coolrail device enables longer linear ablations, and the cryoICE Cryoablation System offers flexible linear ablations of varying lengths.

For electrophysiology, AtriCure provides the EPi-Sense Systems, a single-use disposable device designed for treating persistent atrial fibrillation. The cryoSPHERE probe is another standout, offering temporary pain relief by applying cryothermic energy to intercostal nerves. On the structural side, the AtriClip System is an implantable device for left atrial appendage exclusion, paired with a disposable applier, while the LARIAT System provides a suture-based solution for soft-tissue closure.

Beyond ablation and exclusion, AtriCure supports surgical workflows with tools like Lumitip dissectors for tissue separation, Glidepath guides for clamp placement, and Subtle Cannulas for EPi-Sense catheter access. They also offer a range of reusable cardiac surgery instruments. The company employs a hybrid sales model, using both direct personnel and independent distributors to market and sell their products.

Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a key player in the cardiac surgery and electrophysiology space. Their focus on addressing atrial fibrillation and left atrial appendage management positions them well in the growing market for minimally invasive cardiac procedures.